Lupin Limited said that it has secured approval for Vigabatrin for Oral Solution USP, 500 mg, an anti-epileptic drug, from the US Food and Drug Administration (FDA). The US pharma regulator approved the abbreviated new drug application (ANDA) of the Lupin product, which is a generic of Sabril for Oral Solution, 500 mg owned by […]
Lundbeck, a leading Danish pharmaceutical company, has announced its acquisition of Prexton Therapeutics, a Swiss firm specializing in the development of drugs for Parkinson’s disease, in a deal valued at approximately $1.1 billion. This strategic acquisition is set to enhance Lundbeck’s capabilities in neurology, particularly in the treatment of Parkinson’s disease. Financial Structure of the […]
